CN118647415A - 包含225锕标记的络合物和铋多价螯合剂的药物组合物 - Google Patents

包含225锕标记的络合物和铋多价螯合剂的药物组合物 Download PDF

Info

Publication number
CN118647415A
CN118647415A CN202380018997.0A CN202380018997A CN118647415A CN 118647415 A CN118647415 A CN 118647415A CN 202380018997 A CN202380018997 A CN 202380018997A CN 118647415 A CN118647415 A CN 118647415A
Authority
CN
China
Prior art keywords
pharmaceutical composition
acid
bismuth
group
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380018997.0A
Other languages
English (en)
Chinese (zh)
Inventor
E·卡斯塔尔迪
I·查希
R·福门托卡瓦耶
V·马伊内罗
M·F·马里亚尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN118647415A publication Critical patent/CN118647415A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380018997.0A 2022-02-09 2023-02-09 包含225锕标记的络合物和铋多价螯合剂的药物组合物 Pending CN118647415A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263308211P 2022-02-09 2022-02-09
US63/308,211 2022-02-09
PCT/IB2023/051159 WO2023152671A1 (en) 2022-02-09 2023-02-09 Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent

Publications (1)

Publication Number Publication Date
CN118647415A true CN118647415A (zh) 2024-09-13

Family

ID=85328574

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380018997.0A Pending CN118647415A (zh) 2022-02-09 2023-02-09 包含225锕标记的络合物和铋多价螯合剂的药物组合物

Country Status (5)

Country Link
US (1) US20250161502A1 (https=)
EP (1) EP4475900A1 (https=)
JP (1) JP2025506001A (https=)
CN (1) CN118647415A (https=)
WO (1) WO2023152671A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121793988A (zh) 2023-09-13 2026-04-03 东丽株式会社 癌的治疗、预防和/或诊断用药物组合物
WO2025218879A1 (en) * 2024-04-15 2025-10-23 Itm Technologies Munich Se Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same
WO2025255396A1 (en) * 2024-06-05 2025-12-11 Ariceum Therapeutics Gmbh Radiopharmaceutical composition and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004273775C1 (en) * 2003-03-25 2010-03-04 Sloan-Kettering Institute For Cancer Research Methods for protection from toxicity of alpha emitting elements during radioimmunotherapy
RS65188B1 (sr) 2016-03-22 2024-03-29 Univ Johns Hopkins Sredstva sa visokim afinitetom za ciljano dejstvo na membranski antigen specifičan za prostatu za endoradioterapiju kancera prostate
CN111032632B (zh) * 2017-05-30 2024-04-12 约翰霍普金斯大学 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
JP7801207B2 (ja) 2019-07-08 2026-01-16 ３ベー ファーマシューティカルズ ゲーエムベーハー 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
FI3997103T3 (fi) 2019-07-08 2025-02-03 3B Pharmaceuticals Gmbh Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö
EP4178982A1 (en) * 2020-07-13 2023-05-17 Precirix N.V. Antibody fragment against folr1
IL303925A (en) 2021-01-07 2023-08-01 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
EP4122499A1 (en) 2021-07-23 2023-01-25 3B Pharmaceuticals GmbH Fibroblast activation protein inhibitors and use thereof

Also Published As

Publication number Publication date
JP2025506001A (ja) 2025-03-05
WO2023152671A1 (en) 2023-08-17
EP4475900A1 (en) 2024-12-18
US20250161502A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
AU2004259028C1 (en) Stable radiopharmaceutical compositions and methods for preparation
CN118647415A (zh) 包含225锕标记的络合物和铋多价螯合剂的药物组合物
AU2020349018B2 (en) Methods for radiolabelling GRPR antagonists and their kits
AU2021201914A1 (en) GRPR-antagonists for detection, diagnosis and treatment of GRPR-positive cancer
TW202123976A (zh) 穩定濃縮之放射性醫藥組合物
AU2462592A (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
JP7646637B2 (ja) 画像化及び治療用組成物
US20250313579A1 (en) Ligand compounds comprising a chelating group as a bridging group
CN113195005A (zh) 包含放射性标记的grpr拮抗剂和表面活性剂的药物组合物
RU2855011C1 (ru) Способы мечения радиоактивными изотопами антагонистов grpr и наборы на для их осуществления
KR20220118464A (ko) 암의 영상화 및 치료법을 위한 개선된 약동학을 갖는 화합물
RU2839656C1 (ru) Стабильная концентрированная радиофармацевтическая композиция
WO2026096892A1 (en) Somatostatin binding compositions and methods of use thereof
JP2025530229A (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンドおよびその使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination